Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
Adicet Bio (ACET) Stock Price & Analysis
585 Followers
ACET Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $3.77
Previous Close$1.45
Volume193.82K
Average Volume (3M)1.35M
Market Cap
$120.80M
Enterprise Value-$108.40M
Total Cash (Recent Filing)$247.59M
Total Debt (Recent Filing)$20.04M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 07, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding82,173,503
10 Day Avg. Volume599,703
30 Day Avg. Volume1,350,167
Standard Deviation0.28
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.43
Price to Sales (P/S)157.67
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.59
Enterprise Value/Gross Profit-151.82
Enterprise Value/Ebitda0.81
Forecast
1Y Price Target
$11.67Price Target Upside693.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Adicet Bio News
PremiumCompany Announcements
Adicet Bio’s ADI-270 Gets FDA Fast Track for Cancer Therapy
PremiumCompany Announcements
Adicet Bio Advances with FDA Clearance and Upcoming Trial
PremiumCompany Announcements
Adicet Bio Shareholders Shape Future with Strategic Votes
PremiumCompany Announcements
Adicet Bio’s ADI-001 Gains FDA Fast Track for Lupus Nephritis
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAdicet plans to launch a multi-center, open-label Phase 1 trial to assess the safety and anti-tumor activity of monotherapy ADI-270 in adults with relapsed or refractory clear cell RCC.
InnovationADI-270 is viewed as a potential game-changer for the company considering the prospective commercial indications in the solid tumor market.
Regulatory ApprovalADI-270 receives Fast Track Designation for the potential treatment of patients with metastatic, advanced clear cell renal cell carcinoma.
Bears Say
DevelopmentRechallenged mice showed regrowth of tumor volume to injection levels, could indicate lack of long term effective anti-tumor effects.
Financial PerformanceAdicet reported no revenues.
RisksRisks include commercial, regulatory, development, manufacturing, financial, and liability.
---
Ownership Overview
34.77% Insiders
6.69% Mutual Funds
4.21% Other Institutional Investors
54.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $1.05 and its highest was $3.77 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Aug 07, 2024 which is in 13 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on May 14, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.098.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -$0.36.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,173,500 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is RA Capital Management. It holds Adicet Bio’s shares valued at 18M.
---
Adicet Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (693.88% Upside)
$11.67 (693.88% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 9.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.23%
12-Months-Change
Fundamentals
Return on Equity
-53.25%
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
ACET Stock 12 Month Forecast
Average Price Target
$11.67
▲(693.88% Upside)
Technical Analysis
Best Analysts Covering ACET
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-6.01%
reiterated a buy rating 4 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.01% per trade.
---